Medxy AI

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.

Clinical Updates Wellness & Lifestyle

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

By MedXY 08/02/2025

The MISSION Act reduced travel times to cardiac procedures for veterans distant from VA centers but was linked to higher short-term adverse cardiovascular events for PCI and CABG, highlighting complex trade-offs in access and care quality.

Clinical Updates Wellness & Lifestyle

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY 08/02/2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.

Clinical Updates Wellness & Lifestyle

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

By MedXY 08/02/2025

Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Efficacy of the OurFutures Vaping eHealth Intervention in Preventing Adolescent E-Cigarette Use: Insights from a Landmark Australian Cluster RCT

By MedXY 08/02/2025

A large Australian cluster RCT demonstrates that a school-based eHealth intervention, OurFutures Vaping, significantly reduces adolescent e-cigarette use by 65% compared to usual health education over 12 months.

Clinical Updates Medical News

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

By MedXY 08/02/2025

Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.

Clinical Updates Medical News

Safety and Effectiveness of the Walk ‘n Watch Exercise Protocol in Inpatient Stroke Rehabilitation: Insights from a Canadian Phase 3 Stepped-Wedge Trial

By MedXY 08/02/2025

A Canadian multisite trial demonstrated that the Walk 'n Watch structured exercise protocol significantly improves walking endurance in subacute stroke patients during inpatient rehabilitation without increasing serious adverse events.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights$

Clinical Updates Wellness & Lifestyle

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY 08/02/2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.

Wellness & Lifestyle

Unlocking the Potential of the Soleus Muscle: A Key to Metabolic and Cardiovascular Health

By MedXY 08/02/2025

Learn about the critical role of the soleus muscle in metabolism, blood sugar regulation, and cardiovascular health, and discover effective exercises to enhance its function.

Clinical Updates Wellness & Lifestyle

Fertility Outcomes in Advanced-Stage Classic Hodgkin Lymphoma: BrECADD Versus eBEACOPP in the HD21 Trial

By MedXY 08/02/2025

The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therapy for fertility preservation.

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

Efficacy of the OurFutures Vaping eHealth Intervention in Preventing Adolescent E-Cigarette Use: Insights from a Landmark Australian Cluster RCT

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

Safety and Effectiveness of the Walk ‘n Watch Exercise Protocol in Inpatient Stroke Rehabilitation: Insights from a Canadian Phase 3 Stepped-Wedge Trial

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

Unlocking the Potential of the Soleus Muscle: A Key to Metabolic and Cardiovascular Health

Fertility Outcomes in Advanced-Stage Classic Hodgkin Lymphoma: BrECADD Versus eBEACOPP in the HD21 Trial

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia